Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658681 | 0.99 | SLC6A3 (0.40) | SLC6A3KCNH2GCKMDM4MDM2 | |
| SCHEMBL2657371 | 0.89 | KCNH2 (0.38) | KCNH2GCKMDM4MDM2SMURF1 | |
| SCHEMBL6174485 | 0.88 | KCNH2 (0.39) | KCNH2GCKMDM2 | |
| SCHEMBL6174517 | 0.88 | KCNH2 (0.39) | KCNH2MDM4MDM2 | |
| SCHEMBL6173291 | 0.87 | SLC6A3 (0.39) | SLC6A3KCNH2GCKMDM4MDM2 | |
| SCHEMBL6172615 | 0.85 | SMURF1 (0.37) | KCNH2GCKMDM4MDM2SMURF1 | |
| SCHEMBL6173315 | 0.84 | KCNH2 (0.41) | KCNH2GCKMDM4MDM2 | |
| SCHEMBL6173445 | 0.83 | KCNH2 (0.43) | KCNH2GCKMDM4MDM2 | |
| SCHEMBL2663494 | 0.81 | FFAR2 (0.56) | KCNH2GCK | |
| SCHEMBL2663836 | 0.80 | FFAR2 (0.57) | KCNH2GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311504-B1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6441180-B1 | TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-05-30 | — | — | US | disclosed |
| US-6388088-B1 | ANTIDIABETIC AGENTS | HOFFMAN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369232-B1 | ANTIDIABETIC AGENTS | HOFFMANN-LA ROCHE INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | SLC6A3 2710/4885KCNH2 1679/4885GCK 2/4885 |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | SLC6A3 2710/4885KCNH2 1679/4885GCK 2/4885 |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | GCKR, GCK, PFKL | SLC6A3 2465/4885KCNH2 1466/4885GCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.